TRACTISS ends rituximab hopes for Sjögren’s syndrome

GLASGOW – Rituximab is unlikely to work as a treatment for Sjögren’s syndrome, according to a sneak peak of results from a multicenter study. The study, the Trial of Anti–B Cell Therapy in Patients With Primary Sjögren’s Syndrome (TRACTISS), showed that there were no significant differences...
Source: Skin and Allergy News - Category: Dermatology Source Type: news